What does PHARMACIE FIVEZ do?

PHARMACIE FIVEZ is a pharmacy in Dalhem. Private Limited, started on 19 January 2015, 1 establishment.

What is the address of PHARMACIE FIVEZ?

The registered office of PHARMACIE FIVEZ is located at Rue de Mons(BOM) 2 box B, 4607 Dalhem.

Is PHARMACIE FIVEZ still active?

Yes. According to the CBE (30 October 2026) PHARMACIE FIVEZ is active, legal situation “Normale toestand”, started on 19 January 2015.

Is PHARMACIE FIVEZ registered on Peppol?

Yes, PHARMACIE FIVEZ is registered on the Peppol network with ID 0208:0568820767.

What is the enterprise number of PHARMACIE FIVEZ?

The enterprise number of PHARMACIE FIVEZ is BE0568820767.

When was PHARMACIE FIVEZ founded?

PHARMACIE FIVEZ was founded on 19 January 2015.

Who are the directors of PHARMACIE FIVEZ?

According to the 2025 annual accounts, the directors of PHARMACIE FIVEZ are: Virginie HENRY, Catherine HENRY.

Is PHARMACIE FIVEZ a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 January 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMACIE FIVEZ make in 2025?

PHARMACIE FIVEZ posted a profit after taxes of € 105,732 in financial year 2025.

What is the revenue of PHARMACIE FIVEZ?

As a small company, PHARMACIE FIVEZ is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 192,681.

PHARMACIE FIVEZ (Private Limited) - Dalhem - BE0568820767

Dossier PHARMACIE FIVEZ, printed on 30 October 2026 from databakkes.be/en/0568820767/pharmacie-fivez. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 64 % of short-term debt in 2025; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2022.

Financials

Financial year 2025

PHARMACIE FIVEZ from Dalhem, company number BE0568820767, closed financial year 2025 with a result of € 105,732 after tax. For that financial year PHARMACIE FIVEZ recorded a gross margin of € 192,681 and equity of € 259,426. Compared with financial year 2024, the result moved from € 51,773 to € 105,732. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 259,426

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 105,732

▲ 104% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 87,766

▼ 10% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 67,000 paid out

63 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Wage cost

€ 250

▼ € 54,302 vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,720

▲ € 3,642 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 309,129

▼ 19% vs 2024

€ 50,560 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 67,129

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 34,696

▲ 68% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 189,042 Gross margin 2022: € 189,042 First fiscal year in the series	€ 162,291 Gross margin 2023: € 162,291 ▼ 14% vs 2022 (€ 189,042) Unfavourable step	€ 190,986 Gross margin 2024: € 190,986 ▲ 18% vs 2023 (€ 162,291) Favourable step	€ 192,681 Gross margin 2025: € 192,681 ▲ 1% vs 2024 (€ 190,986) Favourable step	▲ 1%
Profit after taxes	€ 51,144 Profit after taxes 2022: € 51,144 First fiscal year in the series	€ 29,307 Profit after taxes 2023: € 29,307 ▼ 43% vs 2022 (€ 51,144) Unfavourable step	€ 51,773 Profit after taxes 2024: € 51,773 ▲ 77% vs 2023 (€ 29,307) Favourable step	€ 105,732 Profit after taxes 2025: € 105,732 ▲ 104% vs 2024 (€ 51,773) Favourable step	▲ 104%
Equity	€ 139,614 Equity 2022: € 139,614 First fiscal year in the series	€ 168,921 Equity 2023: € 168,921 ▲ 21% vs 2022 (€ 139,614) Favourable step	€ 220,694 Equity 2024: € 220,694 ▲ 31% vs 2023 (€ 168,921) Favourable step	€ 259,426 Equity 2025: € 259,426 ▲ 18% vs 2024 (€ 220,694) Favourable step	▲ 18%
Total debts	€ 796,262 Total debts 2022: € 796,262 First fiscal year in the series	€ 661,694 Total debts 2023: € 661,694 ▼ 17% vs 2022 (€ 796,262) Favourable step	€ 592,704 Total debts 2024: € 592,704 ▼ 10% vs 2023 (€ 661,694) Favourable step	€ 550,115 Total debts 2025: € 550,115 ▼ 7% vs 2024 (€ 592,704) Favourable step	▼ 7%
Cash	€ 156,010 Cash 2022: € 156,010 First fiscal year in the series	€ 96,798 Cash 2023: € 96,798 ▼ 38% vs 2022 (€ 156,010) Unfavourable step	€ 97,789 Cash 2024: € 97,789 ▲ 1% vs 2023 (€ 96,798) Favourable step	€ 87,766 Cash 2025: € 87,766 ▼ 10% vs 2024 (€ 97,789) Unfavourable step	▼ 10%
Land & buildings	€ 518,518 Land & buildings 2022: € 518,518 First fiscal year in the series	€ 501,897 Land & buildings 2023: € 501,897 ▼ 3% vs 2022 (€ 518,518) Unchanged	€ 502,591 Land & buildings 2024: € 502,591 Unchanged (€ 501,897) Unchanged	€ 488,786 Land & buildings 2025: € 488,786 ▼ 3% vs 2024 (€ 502,591) Unchanged	▼ 3%
Retained profit	€ 121,014 Retained profit 2022: € 121,014 First fiscal year in the series	€ 150,321 Retained profit 2023: € 150,321 ▲ 24% vs 2022 (€ 121,014) Favourable step	€ 202,094 Retained profit 2024: € 202,094 ▲ 34% vs 2023 (€ 150,321) Favourable step	€ 240,826 Retained profit 2025: € 240,826 ▲ 19% vs 2024 (€ 202,094) Favourable step	▲ 19%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 67,000 Dividend 2025: € 67,000 Unchanged (€ 0) Unchanged
Bank debt	€ 515,898 Bank debt 2022: € 515,898 First fiscal year in the series	€ 440,919 Bank debt 2023: € 440,919 ▼ 15% vs 2022 (€ 515,898) Favourable step	€ 379,336 Bank debt 2024: € 379,336 ▼ 14% vs 2023 (€ 440,919) Favourable step	€ 309,129 Bank debt 2025: € 309,129 ▼ 19% vs 2024 (€ 379,336) Favourable step	▼ 19%
Balance sheet total	€ 935,876 Balance sheet total 2022: € 935,876 First fiscal year in the series	€ 830,615 Balance sheet total 2023: € 830,615 ▼ 11% vs 2022 (€ 935,876) Unchanged	€ 813,397 Balance sheet total 2024: € 813,397 ▼ 2% vs 2023 (€ 830,615) Unchanged	€ 809,540 Balance sheet total 2025: € 809,540 Unchanged (€ 813,397) Unchanged
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	0.5 Employees (FTE) 2023: 0.5 Unchanged (0.5) Unchanged	0.5 Employees (FTE) 2024: 0.5 Unchanged (0.5) Unchanged	-

Key figures of PHARMACIE FIVEZ, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACIE FIVEZ?

What happened at PHARMACIE FIVEZ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 105,732 (▲ 104% vs 2024). filed late Source: NBB ↗
Jan 19, 2015 New establishment in Visé. KBO
2015 Virginie HENRY became a director. NBB
2015 Catherine HENRY became a director. NBB
Jan 19, 2015 Start of the company according to the CBE. KBO

In short

From € 51,144 profit in 2022 to € 105,732 profit in 2025.

Paid € 102,125 in corporate taxes since 2022.

Best year ever: 2025, with € 105,732 profit.

Paid out € 67,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Virginie HENRY Catherine HENRY

PHARMACIE FIVEZ

Behind PHARMACIE FIVEZ are Virginie HENRY and Catherine HENRY.

Directors

According to the 2025 annual accounts

Virginie HENRY

Director

since 2015

Catherine HENRY

Director

since 2015

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Mons(BOM) 2 box B

4607 Dalhem

2.238.340.821

Place Reine Astrid(VIS) 15

4600 Visé

Active since 19 January 2015

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0568.820.767
VAT number: BE 0568.820.767
Registered office: Rue de Mons(BOM) 2 bus B, 4607 Dalhem
Names & denominations: PHARMACIE FIVEZ
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 January 2015
Peppol: Active · Active since 23 Jan 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗